UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

27916

7590

12/30/2008

VERTEX PHARMACEUTICALS INC. 130 WAVERLY STREET CAMBRIDGE, MA 02139-4242 EXAMINER

DAVIS, ZINNA NORTHINGTON

ART UNIT PAPER NUMBER

1625

DATE MAILED: 12/30/2008

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/743,563	12/22/2003	Jean-Damien Charrier	VPI/02-131 US	5056

TITLE OF INVENTION: CASPASE INHIBITORS AND USES THEREOF

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1510	\$300	\$0	\$1810	03/30/2009

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or <u>Fax</u> (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where n

maintenance fee notifica	tions.				_			correspondence address as rate "FEE ADDRESS" for	
CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address				Fe pa	Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, muhave its own certificate of mailing or transmission.				
vertex pharmaceuticals inc. 130 waverly street Cambridge, ma 02139-4242					(Certificat	e of Mailing or Transı	nission	
				I b Sta ad tra	nereby certify that ates Postal Service dressed to the M Insmitted to the U	this Feet e with su Iail Stop SPTO (57	(s) Transmittal is being fficient postage for firs ISSUE FEE address (1) 273-2885, on the date	deposited with the United t class mail in an envelope above, or being facsimile ate indicated below.	
								(Depositor's name)	
								(Signature)	
								(Date)	
APPLICATION NO.	FILING DATE			FIRST NAMED INVENTO	R	ATTO	DRNEY DOCKET NO.	CONFIRMATION NO.	
10/743,563	12/22/2003	<u> </u>		Jean-Damien Charrier	·	-	VPI/02-131 US	5056	
TITLE OF INVENTION	: CASPASE INHIBITO	RS AND USES TH	IEREC	DF					
				_					
APPLN. TYPE	SMALL ENTITY	ISSUE FEE DU	Έ	PUBLICATION FEE DUE	PREV. PAID IS	SUE FEE	TOTAL FEE(S) DUE	DATE DUE	
nonprovisional	NO	\$1510		\$300	\$0		\$1810	03/30/2009	
EXAM	IINER	ART UNIT		CLASS-SUBCLASS]				
DAVIS, ZINNA I	NORTHINGTON	1625		514-309000	_				
1. Change of corresponde CFR 1.363).	ence address or indication	n of "Fee Address"	(37						
_ ′	ondence address (or Cha B/122) attached.	nge of Correspond	ence	(1) the names of up to 3 registered patent attorneys or agents OR, alternatively,					
_				(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to					
☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Custome Number is required.			mer						
3. ASSIGNEE NAME A		A TO BE PRINTEI	OON '	<u> </u> THE PATENT (print or t	ype)				
PLEASE NOTE: Unl	less an assignee is identi	ified below, no ass	signee	data will appear on the	patent. If an ass	ignee is i	dentified below, the do	ocument has been filed for	
(A) NAME OF ASSIG	•	netion of this form	IS NO	T a substitute for filing as (B) RESIDENCE: (CIT		R COUN	ΓRΥ)		
()				(-,(,		
				_					
Please check the appropr	iate assignee category or	categories (will no	ot be pi	rinted on the patent):	Individual 🖵	Corporat	ion or other private gro	up entity 🖵 Government	
4a. The following fee(s)	are submitted:		41	o. Payment of Fee(s): (Ple	ease first reapply	any pre	viously paid issue fee s	shown above)	
☐ Issue Fee				☐ A check is enclosed.					
☐ Publication Fee (No small entity discount permitted) ☐ Advance Order - # of Copies				☐ Payment by credit card. Form PTO-2038 is attached. ☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any					
				overpayment, to Dep	oosit Account Nu	nber	(enclose ar	n extra copy of this form).	
5. Change in Entity Star	tus (from status indicated is SMALL ENTITY statu	,	7	☐ b. Applicant is no lo	nger claiming SN	IALL EN	TITY status See 37 CE	FR 1.27(g)(2)	
NOTE: The Issue Fee an	d Publication Fee (if requ	uired) will not be a	ccepte	d from anyone other than				e assignee or other party in	
interest as shown by the	records of the United Sta	tes Patent and Trac	lemark	Office.					
Authorized Signature				Date					
Typed or printed name									
This collection of inform an application. Confiden submitting the complete this form and/or suggesti Box 1450, Alexandria, V Alexandria, Virginia 223	tiality is governed by 35 d application form to the ions for reducing this but 7 riginia 22313-1450. DC	FR 1.311. The info U.S.C. 122 and 37 USPTO. Time wi rden, should be sen O NOT SEND FEE	ormation OFR Il vary It to the SOR	on is required to obtain or 1.14. This collection is e depending upon the ind e Chief Information Offi COMPLETED FORMS	retain a benefit be stimated to take ividual case. Any cer, U.S. Patent a TO THIS ADDRI	by the public pu	lic which is to file (and s to complete, includin ts on the amount of tin nark Office, U.S. Depa D TO: Commissioner f	by the USPTO to process) g gathering, preparing, and ne you require to complete utment of Commerce, P.O. for Patents, P.O. Box 1450,	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/743,563	12/22/2003	Jean-Damien Charrier	VPI/02-131 US	5056	
27916 7:	590 12/30/2008		EXAM	IINER	
VERTEX PHAR	MACEUTICALS IN	DAVIS, ZINNA NORTHINGTON			
130 WAVERLY S		ART UNIT PAPER NUMBER			
CAMBRIDGE, M	A 02139-4242		1625		
			DATE MAIL ED: 12/30/200	8	

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

	Application No.	Applicant(s)				
	10/743,563	CHARRIER ET AL.				
Notice of Allowability	Examiner	Art Unit				
	Zinna Northington Davis	1625				
	Zinna Northington Davis	1625				
The MAILING DATE of this communication apper All claims being allowable, PROSECUTION ON THE MERITS IS a herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI- of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this apport or other appropriate communication GHTS. This application is subject to	plication. If not included will be mailed in due course. THIS				
1. \boxtimes This communication is responsive to <u>the IDS and Request</u>	for Continued Examination filed Oct	ober 3, 2008.				
2. The allowed claim(s) is/are 50-80 (now renumbered as 1-3	1, respectively).					
3. Acknowledgment is made of a claim for foreign priority un	der 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) Some* c) None of the:						
 Certified copies of the priority documents have 	been received.					
2. Certified copies of the priority documents have	been received in Application No	·				
Copies of the certified copies of the priority doc	cuments have been received in this	national stage application from the				
International Bureau (PCT Rule 17.2(a)).						
* Certified copies not received:						
Applicant has THREE MONTHS FROM THE "MAILING DATE" on noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		complying with the requirements				
4. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give						
5. \square CORRECTED DRAWINGS (as "replacement sheets") mus	t be submitted.					
(a) ☐ including changes required by the Notice of Draftspers	on's Patent Drawing Review (PTO-	948) attached				
1) ☐ hereto or 2) ☐ to Paper No./Mail Date						
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date	s Amendment / Comment or in the C	Office action of				
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the						
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.						
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. ☐ Notice of Informal P	Patent Application (PTO-152)				
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary					
	Paper No./Mail Dat	te				
 Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 10/03/08 	8), 7. X Examiner's Amendr	ment/Comment				
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance				
	9.					

Application/Control Number: 10/743,563 Page 2

Art Unit: 1625

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

- 2. Authorization for this examiner's amendment was given in a prior telephone interview with Ms. Jennifer Che on May 17, 2007.
- 3. The application has been amended as follows:

New claim 80 has been added as follows:

80. (New) The compound according to claim 62, wherein R² is ethyl.

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

- 4. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on October 3, 2008 has been entered.
- 5. The Information Disclosure Statement filed October 3, 2008 has been considered. The references alone or in combination forms do not teach nor suggest structurally similar compounds as those instantly claimed. There is no motivation to

Application/Control Number: 10/743,563 Page 3

Art Unit: 1625

modify the prior compounds to derive the compounds as claimed. Accordingly, claims

50-80 are allowed.

6. The Examiner's Amendment made above corrects the claim numbering set forth

in the Notice of Allowance mailed May 25, 2007 and July 3, 2008.

7. Any comments considered necessary by applicant must be submitted no later

than the payment of the issue fee and, to avoid processing delays, should preferably

accompany the issue fee. Such submissions should be clearly labeled "Comments on

Statement of Reasons for Allowance."

8. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Zinna N. Davis whose telephone number is 571-272-

0682.

9. Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

/Zinna Northington Davis/

Zinna Northington Davis
Primary Examiner

Group 1600-AU 1625